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Summary  Radiotherapy  is  an  essential  modality  in  the  management  of  lung  cancer.
It  is  used  as  a  single  modality  or  in  combination  with  other  modalities  and  aimed
at  cure  or  palliation.  Recent  advances  in  the  simulation  techniques  or  more  precise
targeting  of  the  tumor  made  radiotherapy  more  effective  tool  in  the  ﬁght  against
lung  cancer.  Using  PET  scan  and  better  gating  for  tumor  motion  are  examples  of
these  advances.
This  brief  review  will  present  summary  of  the  role  of  radiotherapy  in  management
of  lung  cancer.
©  2012  Published  by  Elsevier  Limited  on  behalf  of  King  Saud  Bin  Abdulaziz  University
for  Health  Sciences.  All  rights  reserved.
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adiotherapy  is  used  for  the  treatment  of  NSCLC
n many  ways.  It  is  the  primary  treatment  modality
or locally  advanced  unresectable  tumors,  and  it
s usually  given  concomitantly  with  chemotherapy
1].
In the  postoperative  setting,  it  used  as  an  adju-
ant treatment  for  stage  3  NSCLC  aiming  to  improve
ocal  control.  Radiotherapy  is  also  frequently  used
or the  palliation  of  advanced  and  metastatic  lung
ancer.
Radiotherapy  for  NSCLC  is usually  delivered  using
xternal-beam  radiotherapy  via  a  linear  accelera-
or.  Newer  techniques,  such  as  three-dimensional
onformal  techniques  (3D-CRT)  had  improved  the
oxicity proﬁle  and  allowed  to  escalate  the  dose  by
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ttp://dx.doi.org/10.1016/j.jiph.2012.09.002etter  protection  of  normal  tissues  from  unneces-
ary radiation  [2].
Recently  4D-CRT  planning  techniques  account-
ng for  lung  motion  during  radiotherapy  treatment
ad improved  precision  of  dose  delivery  to  intended
umor  target.
eﬁnitions
onventional radiotherapy
here  very  large  ﬁelds  of  radiation  are  used  to  treat
he tumor  with  a margin  and  regional  lymph  nodes
LNs) electively.
onformal radiotherapyhere  limited  ﬁelds  of  radiation  are  used  to  treat
nly the  primary  tumor  and  involved  lymph  nodes
nly.
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Figure  1  Illustration  of  various  radiation  ﬁelds  for  gross
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should  be  made  while  taking  the  primary  tumor  and
involved LN  to  full  dose  of  60  Gy.tumor  volume  (GTV),  clinical  tumor  volume  (CTV),  and
planning  target  volume  (PTV).
Brachytherapy  is  the  delivery  of  radiation  inside
the airways;  it  is  used  mostly  for  palliative  pur-
poses.
The International  commission  on  Radiation  units
and measurements  deﬁnitions  of  target  volumes
(ICRU 1993,  1999).
Gross tumor volume (GTV)
Macroscopic  extent  of  the  malignant  growth,  e.g.
clinically  palpable  and/or  visualized  by  imaging.
Clinical target volume (CTV)
Anatomical  clinical  concept  that  needs  to  be
deﬁned  before  delineation.  It contains  GTV  and/or
subclinical  disease  which  should  be  eliminated.
Planning target volume (PTV)
Geometrical  concept
A  3-D  expansion  of  the  CTV  to  account  for  all
the geometrical  uncertainties  (for  target  and  organ
at risk  of  motion,  set  up  errors  delineation  and
anatomical  changes  during  treatment)  (see  Fig.  1).
Conventional radiotherapy
Conventional  radiotherapy  is two-dimensional  (2-D)
techniques  where  AP/PA  parallel  opposed  ﬁelds  are
used to  treat  the  primary  tumor  and  mediastinal  LN
with a  relatively  wide  margin  to  account  for  set  up
and motion  errors  due  to  breathing  lung  movement.Figure  2  Field  borders  for  hilar  tumors.
The  ﬁeld  borders  are  usually  deﬁned  based  on
he original  location  of  disease  and  potentially
nvolved lymph  nodes.
Although  such  techniques  are  mostly  used  for
alliative  setting,  it  is  not  advised  to  use  it  for  cura-
ive approach  due  to  poor  results  in  local  control,
urvival and  normal  tissue  toxicity.
Figs. 2  and  3 are  examples  of  ﬁeld  arrangements
o treat  tumors  at  different  locations.
onventional deﬁnition of radiotherapy
urative  doses
P/PA  parallel  opposed  ﬁelds  can  be  used  until  a
ose of  46  Gy.  Then  effort  to  spare  the  spinal  cordFigure  3  Field  borders  for  lower  lobe  tumors.
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Sadiotherapy  for  NSCLC  
or post portative radiotherapy
 R1  resection  (residual  microscopic  disease);
54 Gy  to  bronchial  stump.
R2  resection  (residual  macroscopic  disease);
60—66 Gy  to  Bronchial  stump.
 Multiple  N2  lymph  nodes  or  extra  capsular  exten-
sion shrinkage  ﬁeld  technique  after  the  dose  of
46 Gy  taking  the  diseased  area  to  60—66  Gy.
Daily fractionation  of  1.8—2  Gy  per  day.
ecent advances in radiotherapy for
SCLC
ne  of  the  many  challenges  of  lung  cancer  radio-
herapy  is  conforming  radiation  to  the  target  due
o tumor/organ  motion  and  the  need  to  spare  sur-
ounding  critical  structures.
Control  of  local  disease  using  conventional  two-
imensional  (2-D)  radiotherapy  planning  to  a total
ose of  60—66  Gy,  has  been  poor  (only  in  30—50%
f cases),  and  dose  escalation  has  been  associated
ith increased  toxicity,  particularly  when  concur-
ent chemotherapy  is  given  [3]
Three main  factors  contribute  to  local  treatment
ailure after  radiotherapy:
1)  Geographic  misses  due  to  inadequacy  of  imag-
ing tools  for  staging  and  radiotherapy  planning;
2) Geographic  misses  due  to  respiration-induced
tumor  motion  and  anatomic  changes  during
radiation delivery;  and
3) Inadequate  radiation  dose  due  to  concerns
about toxicity.
Recent  developments  in  radiotherapy  are  for
ung cancer  can  be  summarized  by  the  following
oints:
 Positron  emission  tomography/computed  tomo-
graphy  (PET/CT)  has  been  shown  to  improve
targeting accuracy  in  25—50%  of  cases.
4-D  planning  by  accounting  for  tumor  motion.
 Daily  on-board  imaging  reduces  treatment  set-up
uncertainty  and  provides  information  about  daily
organ motion  and  variations  in  anatomy.
 Image-guided  intensity-modulated  radiotherapy
(IMRT) may  allow  for  the  escalation  of  radiothe-
rapy dose  with  no  increase  in  toxicity.
 Image-guided  stereotactic  radiotherapy  can
achieve  local  control  rates  exceeding  90%
through the  use  of  focused,  hypo-fractionated,
highly  biologically  effective  doses.
These  new  approaches  were  considered  experi-
ental for  many  years,  but  recently  accumulating
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vidence  of  their  potential  for  signiﬁcantly  improv-
ng clinical  outcomes  is  leading  to  their  inclusion
n standard  treatments  for  lung  cancer  at  major
ancer  centers  [4].
DG-PET/CT role in NSCLC radiotherapy
reatment
DG-PET/CT  has  become  an  integral  component  of
SCLC staging  because  it  improves  the  detection  of
odal and  distant  metastases  and  frequently  alters
atient  management  [5].
Functional  imaging  is  increasingly  utilized  for
reatment  planning  for  patients  with  NSCLC.
ncorporation of  FDG  PET  images  into  radiation
herapy treatment  planning  resulted  in  a  15—60%
ncrease  or  decrease  in  treated  volumes.  Ulti-
ately, improvement  in  outcomes  will  determine
he widespread  use  of  FDG  PET/CT  in  radiation
herapy treatment  planning  [6,7].
umor motion management
 major  obstacle  to  radiotherapy  in  lung  cancer
as been  respiration-induced  target  motion  (also
nown as  intrafractional  tumor  motion),  which
an add  considerable  geometric  uncertainty  to
reatment,  particularly  for  highly  conformal  radio-
herapy treatment  delivery  techniques  such  as  IMRT
r SRBT.
The  ideal  solution  to  this  problem  would  be  to
rack the  tumor  in  real  time  during  treatment  and
orrect beam  position  to  match  the  location  of  the
arget.
Internal gross  tumor  volume  (IGTV),  which
nvelops the  GTV  motion  throughout  the  respi-
atory  cycle,  delineating  the  IGTV  from  4-D  CT
mages  involves  outlining  the  tumor  volume  on  the
xpiratory-phase  images  and  then  registering  the
utline to  the  images  from  other  phases  to  cre-
te a union  of  target  contours  enclosing  all  possible
ositions  of  the  target.
If  4-D  CT  is  not  available,  alternative  approaches
o address  tumor  motion  should  be  considered;  for
nstance, the  IGTV  can  be  delineated  by  combin-
ng volumes  on  breath-hold  spiral  CT  at  the  end  of
xpiration  and  at the  end  of  inspiration,  for  patients
ho can  comply  with  this  technique.
tereotactic body radiation therapy (SBRT)wo  important  principles  of  SBRT  must  be  obeyed:
1) An  ablative  dose  (biological  effective  dose,  BED,
100 Gy)  is  required  to  achieve  >90%  local  control,
nd (2)  image-guided  tumor  volume  delineation  and
RS48  
on-board  image-guided  radiation  delivery  (IGRT)
are required  to  ensure  that  the  target  is  not  missed
and to  avoid  normal  tissue  injury.  An  ablative  dose
of SBRT  is typically  delivered  in  <5  fractions.  With
such a  small  number  of  fractions,  it  is  critical  that
patient positioning  and  target  coverage  be  opti-
mized  for  each  treatment.  Toxicity  may  be  severe
even  fatal  if  critical  normal  tissue  receives  an
excess dose  of  radiation.  Conformal  SBRT  is  there-
fore usually  optimized  to  ensure  that  at  least  95%
of the  prescribed  dose  (minimum  BED  of  100  Gy)
is delivered  to  the  PTV  which  is  usually  deﬁned  as
the IGTV  plus  a  small  margin  to  account  for  set-up
uncertainty  [8].
It  has  been  shown  that  this  approach  can  achieve
100% local  control  with  minimal  side  effects  (<grade
3) in  centrally  located  lesions  [9].
Conclusion
New  technologies  are  evolving  to  improve  confor-
mality of  radiation  therapy  to  help  focus  the  high
dose on  the  target  and  spare  critical  normal  tissue.
Treatment  planning  based  on  4-D  CT  images  and  on-
board image-guided  adaptive  treatment  delivery
helps  the  radiation  oncologist  track  tumor  motion
and target  the  tumor  precisely.  Improved  treatment
accuracy  and  conformality  in  SBRT  enable  us  to
deliver doses  high  enough  to  ablate  the  cancer  com-
pletely with  minimal  toxicity  in  early-stage  NSCLC.
For stage  III  disease,  image-guided,  individual-
ized IMRT  with  dose  escalation/acceleration  can
potentially  reduce  toxicity  and  increase  the  cure
rate. Further  studies  to  optimize  treatment  plan-
ning, including  dose  painting  in  high-risk  areas
within  the  target,  are  still  needed  [10].
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